Liquidia (NASDAQ:LQDA) General Counsel Sells $1,021,427.27 in Stock

Liquidia Corporation (NASDAQ:LQDA) General Counsel Russell Schundler sold 27,289 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $1,021,427.27. Following the transaction, the general counsel directly owned 579,394 shares in the company, valued at approximately $21,686,717.42. This represents a 4.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Russell Schundler also recently made the following trade(s):

• On Monday, December 1st, Russell Schundler sold 1,072 shares of Liquidia stock. The shares were sold at an average price of $32.19, for a total value of $34,507.68.

Liquidia Stock Up 4.1%

Shares of NASDAQ LQDA traded up $1.49 during midday trading on Tuesday, hitting $38.09. 2,055,159 shares of the stock traded hands, compared to its average volume of 2,814,845. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20. Liquidia Corporation has a one year low of $11.26 and a one year high of $39.29. The business has a 50 day moving average price of $31.94 and a two-hundred day moving average price of $25.40. The company has a market cap of $3.31 billion, a PE ratio of -26.45, a P/E/G ratio of 1.19 and a beta of 0.48.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The business had revenue of $54.34 million during the quarter, compared to the consensus estimate of $18.86 million. The business’s revenue was up 1106.7% on a year-over-year basis. On average, equities analysts predict that Liquidia Corporation will post -1.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on LQDA. HC Wainwright raised their price target on shares of Liquidia from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Wall Street Zen upgraded Liquidia from a “hold” rating to a “buy” rating in a report on Saturday. Wells Fargo & Company began coverage on Liquidia in a research report on Monday, October 20th. They set an “overweight” rating and a $31.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research report on Wednesday, October 8th. Finally, Needham & Company LLC raised their price objective on Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Liquidia currently has an average rating of “Moderate Buy” and an average price target of $39.67.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Short interest fell materially in December — short interest declined 18.1% to 10,709,682 shares as of Dec. 31 (about 17.6% of shares were sold short) and the days-to-cover was ~11.6. Fewer active shorts can reduce downside pressure and may have contributed to the stock moving higher. (Market data entry)
• Neutral Sentiment: January short-interest data shows 0 shares as of Jan. 12 — this is almost certainly a reporting or data glitch rather than a real liquidation of all short positions. Investors should monitor the next short-interest report for a corrected figure. (Market data entry)
• Negative Sentiment: CEO Roger Jeffs sold 66,610 shares at an average $37.43 (≈$2.49M); his stake decreased ~6.03%. This large insider sale may be seen as a negative signal by some investors. SEC Filing
• Negative Sentiment: CFO Michael Kaseta sold 36,932 shares at $37.43 (≈$1.38M); his holding fell ~9.52%. SEC Filing
• Negative Sentiment: General Counsel Russell Schundler sold 27,289 shares at $37.43 (≈$1.02M); his holding fell ~4.50%. SEC Filing
• Negative Sentiment: Other insiders (including Rajeev Saggar, Jason Adair, Scott Moomaw, Sarah Krepp, CAO Dana Boyle) also executed sales on Jan. 12 at ~$37.43 per share, each reducing positions between ~6–11.7%. These combined sales represent significant insider liquidity taken at current prices. Rajeev Saggar SEC Filing Dana Boyle SEC Filing Jason Adair SEC Filing Scott Moomaw SEC Filing Sarah Krepp SEC Filing

Institutional Trading of Liquidia

Institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd purchased a new position in Liquidia in the second quarter worth $1,485,000. Tyro Capital Management LLC purchased a new stake in shares of Liquidia during the 2nd quarter valued at $15,473,000. Diametric Capital LP raised its stake in shares of Liquidia by 72.5% during the 2nd quarter. Diametric Capital LP now owns 148,601 shares of the company’s stock worth $1,852,000 after purchasing an additional 62,443 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in shares of Liquidia in the 2nd quarter worth about $775,000. Finally, Pale Fire Capital SE purchased a new position in shares of Liquidia in the 2nd quarter worth about $1,068,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).